|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 551.30 DKK | -4.22% |
|
-10.08% | -11.68% |
| Jan. 03 | New Year, Soft Start |  |
| Jan. 03 | BNP Paribas Exane Cuts Novo Nordisk PT, Maintains at Outperform | MT |
| Capitalization | 2,448B 341B 328B 310B 278B 489B 29,426B 545B 3,765B 1,395B 12,140B 1,280B 1,254B 53,134B | P/E ratio 2024 * |
24.7x | P/E ratio 2025 * | 20.1x |
|---|---|---|---|---|---|
| Enterprise value | 2,508B 350B 336B 317B 284B 501B 30,150B 558B 3,857B 1,429B 12,439B 1,312B 1,285B 54,443B | EV / Sales 2024 * |
8.76x | EV / Sales 2025 * | 7.13x |
| Free-Float |
70.25% | Yield 2024 * |
1.98% | Yield 2025 * | 2.53% |
More valuation ratios
* Estimated data
More news
Last Transcript: Novo Nordisk A/S
| NOVO NORDISK : UBS gives a Buy rating | 02:02am | ZD |
| Novo Nordisk is far too cheap according to equity strategist - Di | Jan. 20 | FW |
| NOVO NORDISK : Bernstein remains Neutral | Jan. 17 | ZD |
| NOVO NORDISK : JP Morgan keeps its Buy rating | Jan. 17 | ZD |
| NOVO NORDISK : UBS keeps its Buy rating | Jan. 17 | ZD |
More press releases
| 1 day | -4.22% | ||
| 1 week | -10.08% | ||
| Current month | -11.68% | ||
| 1 month | -6.43% | ||
| 3 months | -31.70% | ||
| 6 months | -39.16% | ||
| Current year | -11.68% |
1 week
550.10
606.60
1 month
550.10648.90
Current year
550.10640.80
1 year
526.001 033.20
3 years
302.201 033.20
5 years
165.851 033.20
10 years
109.101 033.20
| Director | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 59 | 2016-12-31 | |
| Director of Finance/CFO | 54 | 2018-02-14 | |
| Chief Tech/Sci/R&D Officer | 55 | 2018-12-31 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 63 | 2015-03-18 |
Kasim Kutay
BRD | Director/Board Member | 60 | 2017-03-22 |
Helge Lund
CHM | Chairman | 62 | 2018-03-21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 21.31% | 209 M€ | +1.76% | ||
| 10.45% | 4 M€ | +3.33% | ||
| 5.40% | 30 M€ | +1.14% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -4.22% | -10.08% | -24.73% | +73.23% | 341B | ||
| -4.21% | -9.00% | +15.45% | +198.49% | 653B | ||
| -0.50% | +1.77% | -9.06% | -11.03% | 354B | ||
| -1.23% | -2.93% | +4.12% | +28.96% | 303B | ||
| -2.76% | -3.03% | -17.64% | +21.26% | 248B | ||
| +0.57% | +0.76% | +9.34% | -26.90% | 236B | ||
| -1.32% | -0.26% | +2.72% | +22.08% | 206B | ||
| -0.10% | -1.72% | -4.87% | +9.63% | 197B | ||
| -0.72% | -1.87% | -7.00% | -51.34% | 149B | ||
| +0.99% | +0.71% | -11.60% | +18.88% | 146B | ||
| Average | -1.35% | -1.83% | -4.33% | +28.33% | 283.38B | |
| Weighted average by Cap. | -1.96% | -3.21% | -1.98% | +56.47% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 286B 39.9B 38.37B 36.22B 32.44B 57.14B 3,440B 63.72B 440B 163B 1,419B 150B 147B 6,212B | 347B 48.42B 46.56B 43.95B 39.36B 69.33B 4,174B 77.32B 534B 198B 1,722B 182B 178B 7,537B |
| Net income | 101B 14.02B 13.49B 12.73B 11.4B 20.08B 1,209B 22.39B 155B 57.32B 499B 52.6B 51.51B 2,183B | 124B 17.23B 16.57B 15.64B 14.01B 24.68B 1,486B 27.52B 190B 70.44B 613B 64.63B 63.3B 2,683B |
| Net Debt | 60.27B 8.4B 8.08B 7.63B 6.83B 12.03B 724B 13.42B 92.68B 34.34B 299B 31.51B 30.86B 1,308B | 26.59B 3.71B 3.56B 3.37B 3.01B 5.31B 320B 5.92B 40.89B 15.15B 132B 13.9B 13.62B 577B |
More financial data
* Estimated data
Employees
71,880
Sector
Pharmaceuticals
Calendar
2025-02-05
- Q4 2024 Earnings Release
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-01-20 | 551.30 kr | -4.22% | 3,884,536 |
| 25-01-17 | 575.60 kr | -4.34% | 6,386,278 |
| 25-01-16 | 601.70 kr | -0.55% | 3,148,513 |
| 25-01-15 | 605.00 kr | +2.14% | 4,160,081 |
| 25-01-14 | 592.30 kr | -3.39% | 4,975,042 |
Delayed Quote Nasdaq Copenhagen, January 20, 2025 at 11:20 am EST
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
551.30DKK
Average target price
830.68DKK
Spread / Average Target
+50.68%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NOVO B Stock
